+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07891923

Evaluating Less Frequent Daratumumab Dosing with VRd Therapy for Adults with Newly Diagnosed Multiple Myeloma in a Phase 2 Trial

Led by Tata Memorial Centre · Updated on 2026-10-27

52

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a modified, less frequent dosing schedule of daratumumab combined with standard VRd therapy bortezomib, lenalidomide, and dexamethasone for treating adults with newly diagnosed multiple myeloma. This phase 2, single-arm study aims to see if this approach increases the rate of minimal residual disease MRD negativity after four cycles of induction therapy, while also assessing safety, drug levels, and clinical response. Participants will receive four 28-day cycles of induction therapy including daratumumab given intravenously on days 1, 15, 29, 50, 71, and 92 weekly subcutaneous bortezomib oral lenalidomide daily for 21 days followed by a 7-day break and weekly dexamethasone. After induction, transplant-eligible patients may proceed to autologous stem cell transplant, while others continue VRd therapy for up to 9-12 cycles followed by maintenance treatment. During the study, participants will undergo bone marrow testing for MRD within two weeks after cycle 4, along with blood tests after cycles 2 and 4 to monitor treatment response. Researchers will also assess progression-free survival over two years, safety, pharmacokinetics of daratumumab, stem cell yield, and time to engraftment for transplant patients. Immune cell subsets will be explored as part of the research outcomes. The study duration is planned for four years.

CONDITIONS

Brief Title

Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma

Research Team

D

Dr.Sumeet Mirgh, MBBS MD DM Clinical Hematology

D

Dr. Anant Gokarn, MBBS MD DM Medical Oncology

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here